class='kwd-title'>Keywords: Oral administration,'/> Facile fabrication of microparticles with pH-responsive macropores for small intestine targeted drug formulation
首页> 美国卫生研究院文献>Elsevier Sponsored Documents >Facile fabrication of microparticles with pH-responsive macropores for small intestine targeted drug formulation
【2h】

Facile fabrication of microparticles with pH-responsive macropores for small intestine targeted drug formulation

机译:易于制造具有pH响应大孔的小肠靶向药物制剂的微粒

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="kwd-title">Keywords: Oral administration, Drug delivery, Microparticles, Macropore, Gastrointestinal tract, pH, Emulsion class="head no_bottom_margin" id="ab010title">AbstractOral drugs present the most convenient, economical, and painless route for self-administration. Despite commercialization of multiple technologies relying on micro- and nanocrystalline drugs, research on microparticles (MPs) based oral biopharmaceuticals delivery systems has still not culminated well enough in commercial products. This is largely due to the drugs being exposed to the destabilizing environment during MP synthesis process, and partly because of complicated process conditions. Hence, we developed a solvent swelling-evaporation method of producing pH-responsive MPs with micron-sized macropores using poly(methacrylic acid-co-ethyl acrylate) in 1:1 ratio (commercial name: Eudragit® L100-55 polymer). We investigated the effects of temperature and evaporation time on pore formation, freeze-drying induced pore closure, and the release profile of model drugs (fluorescent beads, lactase, and pravastatin sodium) encapsulated MPs in simulated gastrointestinal tract conditions. Encapsulated lactase/pravastatin maintained >60% of their activity due to the preservation of pore closure, which proved the potential of this proof-of-concept microencapsulation system. Importantly, the presence of macropores on MPs can be beneficial for easy drug loading, and solve the problem of bioactivity loss during the conventional MP fabrication-drug encapsulation steps. Therefore, pH-sensing MPs with macropores can contribute to the development of oral drug formulations for a wide variety of drugs and bio-macromolecules, having a various size ranging from genes to micron-sized ingredients with high therapeutic efficacy.
机译:<!-fig ft0-> <!-fig @ position =“ anchor” mode =文章f4-> <!-fig mode =“ anchred” f5-> <!-fig / graphic | fig / alternatives / graphic mode =“ anchored” m1-> class =“ kwd-title”>关键字:口服,药物输送,微粒,大孔,胃肠道,pH,乳液 class =“ head no_bottom_margin“ id =” ab010title“>摘要口服药物是自我管理最便捷,最经济,最轻松的途径。尽管依赖微和纳米晶体药物的多种技术已商业化,但对基于微粒(MPs)的口服生物药物输送系统的研究在商业产品中仍未达到最高水平。这在很大程度上是由于药物在MP合成过程中暴露于不稳定的环境中,部分原因是由于复杂的过程条件。因此,我们开发了一种溶剂溶胀蒸发方法,该方法使用比例为1:1的聚(甲基丙烯酸-丙烯酸乙酯)来生产具有微米级大孔的pH响应型MP(商品名:Eudragit®L100-55聚合物)。我们研究了温度和蒸发时间对模拟胃肠道条件下MPs孔形成,冻干诱导的孔闭合以及模型药物(荧光珠,乳糖酶和普伐他汀钠)封装的MPs释放曲线的影响。胶囊化的乳糖酶/普伐他汀由于保留了孔封闭而保持了其活性的60%以上,这证明了这种概念验证的微胶囊化系统的潜力。重要的是,MP上大孔的存在有利于药物的轻松装载,并解决了传统MP制造-药物封装步骤中生物活性降低的问题。因此,具有大孔的pH敏感MPs有助于开发用于多种药物和生物大分子的口服药物制剂,其具有从基因到微米大小的各种大小的大小,具有很高的治疗功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号